

T-Cell Acute Lymphoblastic Leukemia/Lymphoma
(ALL), FISH, Adult, Varies

Patient ID SA00148951	Patient Name TESTINGRNV, TALAF-ABNORMAL	Birth Date 1961-10-29	Gender M	Age 59
Order Number SA00148951	Client Order Number SA00148951	Ordering Physician CLIENT,CLIENT	Report Notes	
Account Information C7028846 DLMP Rochester		Collected 13 Oct 2021 15:42		

Adult ALL (T-cell), FISH

Result Summary

MCR

Abnormal

Interpretation

MCR

The result is abnormal and indicates 90% of nuclei had LMO2/TRAD fusion. At diagnosis, LMO2/TRAD fusion has been associated with an intermediate to favorable prognosis in T-lymphoblastic leukemia/lymphoma (T-ALL) (Roberts et al., Nat Rev Clin Oncol 12:344–357, 2015).

Clinical and pathologic correlation is recommended.

For monitoring response to therapy, FISH for LMO2/TRAD is available, test TALMF [ALL (T-cell), Specified FISH].

Result Table

MCR

Abnormality Name	Result	Abn%	Cutoff%
14q11.2(TRAD sep)	Abnormal	90	<15.0
t(11;14) LMO2/TRAD fusion	Abnormal	90	<4.0
t(10;14) TLX1/TRAD fusion	Normal		<4.0
11q23(MLL sep)	Normal		<10.0
t(9;22) ABL1/BCR fusion	Normal		<4.0
9p24.1(JAK2 sep)	Normal		<10.0
5q33(PDGFRB sep)	Normal		<15.0
t(5;14) TLX3/BCL11B fusion	Normal		<4.0
7q34(TRB sep)	Normal		<15.0
t(10;11) MLLT10/PICALM fusion	Normal		<4.0
9q34(ABL1 sep)	Normal		<15.0
1p33(TAL1/STIL sep)	Normal		<10.0
t(10;14) TLX1/TRAD fusion	Normal		<4.0

Result

MCR

nuc ish(LMO2,TRAD)x3(LMO2 con TRADx2)[180/200]

Reason for Referral

MCR

T-acute lymphoblastic leukemia

Specimen

MCR

Bone Marrow

Source

MCR

Left iliac crest

Method

MCR

Locus and probes	[Strategy;#Nuclei;Class]
1p33(TAL1,STIL)	[BAP;100;LDT]
5q33(3'PDGFRB,5'PDGFRB)	[BAP;100;LDT]
5q35(TLX3), 14q32(BCL11B)	[DFISH;200;LDT]
7q34(5'TRB,3'TRB)	[BAP;100;LDT]
9p24(5'JAK2,3'JAK2)	[BAP;100;LDT]
9q34(5'ABL1,3'ABL1)	[BAP;100;LDT]
9q34(ABL1), 22q11.2(BCR)	[DFISH;200;AM]
10p12(MLLT10), 11q14(PICALM)	[DFISH;200;LDT]
10q24(TLX1), 14q11.2(TRAD)	[DFISH;200;LDT]
11p13(LMO2), 14q11.2(TRAD)	[DFISH;200;LDT]
11q23(5'MLL[KMT2A],3'MLL[KMT2A])	[BAP;100;AM]
14q11.2(5'TRAD,3'TRAD)	[BAP;100;LDT]

Probe strategies include:
DFISH=dual color, double fusion;
BAP=break-apart probe.
Scoring Method: Manual

Probe vendors include:
LDT = Mayo Clinic Developed
AM = Abbott Molecular, Inc (Des Plaines, IL)

Performing Site Legend

Code	Laboratory	Address	Lab Director	CLIA Certificate
MCR	Mayo Clinic Laboratories - Rochester Main Campus	200 First Street SW, Rochester, MN 55905	William G. Morice M.D. Ph.D	24D0404292

Report Status: Final



Patient ID SA00148951	Patient Name TESTINGRNV, TALAF-ABNORMAL	Birth Date 1961-10-29	Gender M	Age 59
Order Number SA00148951	Client Order Number SA00148951	Ordering Physician CLIENT,CLIENT	Report Notes	
Account Information C7028846 DLMP Rochester		Collected 13 Oct 2021 15:42		

Disclaimer

MCR

Applicable to Analyte Specific Reagent (ASR) and Laboratory Developed Tests (LDT). This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the U.S. Food and Drug Administration. This FISH test does not rule out other chromosome abnormalities.

Released By

MCR

Jess F. Peterson, M.D.

Received: 15 Oct 2021 07:23

Reported: 25 Oct 2021 11:02

Performing Site Legend

Code	Laboratory	Address	Lab Director	CLIA Certificate
MCR	Mayo Clinic Laboratories - Rochester Main Campus	200 First Street SW, Rochester, MN 55905	William G. Morice M.D. Ph.D	24D0404292